Sponsor intelligence · OTHER
Clinical trials sponsored by
Shanghai Zhongshan Hospital.
Real, source-linked trial activity for Shanghai Zhongshan Hospital: 11 tracked trials, by phase and status, newest first. New trials = pipeline expansion = CRO, site, and reagent demand.
✔ Verified against the public NIH RePORTER & ClinicalTrials.gov records as of Sep 19, 2026. Source-linked, daily-refreshed.
N/A 6NA 3PHASE4 1PHASE1/PHASE2 1
Newest Shanghai Zhongshan Hospital trials
| Posted | Trial | Phase | Status | |
|---|---|---|---|---|
| 9d ago | TEE-Guided Versus CCTA-Guided Preprocedural Imaging for Left Atrial Ap | NA | RECRUITING | ↗ |
| 9d ago | OPtimization of Antiplatelet Therapy After the intervenTION of de Novo | Ph 4 | NOT_YET_RECRUITING | ↗ |
| 18d ago | A Multicenter Prospective Study Evaluating the Diagnostic Performance | N/A | NOT_YET_RECRUITING | ↗ |
| 20d ago | A Multicenter, Prospective Study on the Diagnostic Efficacy of Femtose | N/A | NOT_YET_RECRUITING | ↗ |
| 25d ago | Biomarker and Mechanism Study of Systemic Therapy in Unresectable HCC | N/A | NOT_YET_RECRUITING | ↗ |
| 32d ago | ICCA-Based ICU Physiological State Space Monitor | N/A | ACTIVE_NOT_RECRUITING | ↗ |
| 53d ago | Peripheral Blood Biomarkers and Response to Atezolizumab Plus Bevacizu | N/A | NOT_YET_RECRUITING | ↗ |
| 53d ago | LineMatrix® Biological Vascular Graft for Infra-renal Arterial Bypass | NA | NOT_YET_RECRUITING | ↗ |
| 55d ago | Evaluate the Diagnostic Efficacy and Safety of INR 202 PET/CT Imaging | NA | NOT_YET_RECRUITING | ↗ |
| 58d ago | The Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodie | N/A | NOT_YET_RECRUITING | ↗ |
| 62d ago | Phase Ib/II Multicenter Randomized Control Study of Peri-operative Tre | Ph 1/Ph 2 | NOT_YET_RECRUITING | ↗ |
Get this lane pushed to you the day a new grant or trial lands
Free email digest + a daily new-funding feed (JSON / MCP / webhook) of newly-awarded NIH grants and newly-registered clinical trials for Shanghai Zhongshan Hospital (trial sponsor). Watch institutions, PIs, sponsors, and topics. Newly-funded labs = new buyers, today.